MELI vs PFE: Which Is the Better Buy?
Side-by-side comparison of MercadoLibre, Inc. and Pfizer Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-04-11.
MercadoLibre, Inc. · Consumer Cyclical
$1,767.42
+41.4% upside to fair value
High Conviction
Grade A
VS
Pfizer Inc. · Healthcare
$26.91
+30.1% upside to fair value
Med Conviction
Grade B+
QuantHub Verdict
MELI has more upside to fair value
(+41.4%).
PFE trades at a lower forward P/E
(9.5x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
MELI |
PFE |
| Current Price |
$1,767.42 |
$26.91 |
| Fair Value Estimate |
$2,500.00 |
$35.00 |
| Upside to Fair Value |
+41.4%
|
+30.1%
|
| Market Cap |
$89.6B |
$153.0B |
| Forward P/E |
35.0x
|
9.5x
|
| EV / EBITDA |
18.5x
|
13.8x
|
| Price / Sales |
3.1x
|
2.4x
|
| Price / FCF |
8.9x
|
16.8x
|
| Revenue Growth YoY |
+39.1%
|
-1.6%
|
| Gross Margin |
44.5%
|
70.3%
|
| Operating Margin |
11.1%
|
24.7%
|
| Return on Equity |
33.7%
|
9.0%
|
| Dividend Yield |
0% |
6.4% |
| FCF Yield |
12.1%
|
5.9%
|
| Analyst Consensus |
Strong Buy
|
Hold
|
Investment Thesis
MercadoLibre is the dominant e-commerce and fintech ecosystem across Latin America, operating the largest marketplace and digital payments platform in a region with 670M+ people where e-commerce penetration is still under 15%. Revenue grew 39% to $28.9B in FY2025 with $10.8B in free cash flow — a 12% FCF yield at current prices. The company is trading at its 5-year P/S minimum (3.1x) and P/FCF mi…
Pfizer remains the world's largest traditional pharmaceutical company by non-COVID revenue, generating $62.6B in 2025 sales across oncology, cardiovascular, immunology, and vaccines. The stock trades at a P/S of 2.44x, still well below the 5-year median of 3.10x, driven by post-COVID revenue normalization, a $17-18B patent cliff spanning 2026-2028, and $61.6B in acquisition-related debt from Seag…
Accumulation Zones
| Metric |
MELI |
PFE |
| Zone Low |
$1,875.00 |
$25.00 |
| Zone High |
$2,125.00 |
$29.00 |
| In Buy Zone? |
Yes
|
Yes
|